(2S)-2-甲氧基丙烷-1-胺 | 907943-71-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (2S)-2-甲氧基丙烷-1-胺
• 中文别名: (S)-2-甲氧基丙胺
• 英文名称: (2S)-2-methoxypropan-1-amine
• CAS: 907943-71-9
• 化学式: C₄H₁₁NO
• mdl: MFCD08146657
• 分子量: 89.1374
• InChiKey: UANWURKQKKYIGV-BYPYZUCNSA-N

物化性质

• 沸点：
  100.7±13.0 °C(Predicted)
• 密度：
  0.849±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险类别：
  3,8
• 危险性防范说明：
  P210,P264,P240,P242,P243,P270,P271,P280,P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P330,P363,P370+P378,P403+P233,P501
• 危险品运输编号：
  2733
• 危险性描述：
  H225,H302,H314,H412
• 包装等级：
  II

反应信息

• 作为反应物：
  描述：

  (2S)-2-甲氧基丙烷-1-胺 、 2-[(3S,4R)-4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-3-methoxy-1-piperidyl]-5-ethoxycarbonyl-thiazole-4-carboxylic acid 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以63%的产率得到ethyl 2-[(3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl]-4-{[(2S)-2-methoxypropyl]carbamoyl}-1,3-thiazole-5-carboxylate
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x
• 作为产物：
  描述：

  (S)-2-甲氧基丙-1-胺盐酸盐 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 (2S)-2-甲氧基丙烷-1-胺
  参考文献：
  名称：

  Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline

  摘要：

  DOI：

  10.1021/acs.oprd.3c00287

文献信息

• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• Regioselective and Enantioselective Hydroformylation of Dialkylacrylamides
  作者：Gary M. Noonan、David Newton、Christopher J. Cobley、Andrés Suárez、Antonio Pizzano、Matthew L. Clarke

  DOI：10.1002/adsc.200900871

  日期：——

  possible, provided steps are taken to minimise racemisation of the aldehyde products, and this work demonstrates the effect of various conditions and variables on racemisation. Using the Landis diazaphospholane ligands up to 68% ee can be realised under very mild conditions. Other dialkylacrylamides were also hydroformylated under mild conditions giving similar or better enantioselectivities, including

  二甲基丙烯酰胺可以以很高的化学和区域选择性加氢甲酰化。该底物的不对称加氢甲酰化是可能的，只要采取步骤使醛产物的外消旋化最小化即可，并且这项工作证明了各种条件和变量对外消旋化的影响。在非常温和的条件下，使用Landis二氮磷杂环戊烷配体可以达到ee的68％。其他二烷基丙烯酰胺也可在温和条件下加氢甲酰化，得到相似或更好的对映选择性，包​​括丙烯酸的Weinreb酰胺（71％ee），以及二乙基丙烯酰胺的不对称加氢甲酰化生成手性醛，ee最高可达82％。
• [EN] INHIBITORS OF RAF KINASES<br/>[FR] INHIBITEURS DE KINASES RAF
  申请人：KINNATE BIOPHARMA INC

  公开号：WO2021081375A1

  公开（公告）日：2021-04-29

  Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

  本文提供了抑制受体酪氨酸激酶效应子RAF的药物，包括所述化合物的药物组合物，以及使用这些化合物治疗疾病的方法。
• [EN] CBL-B MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE CBL-B ET LEURS UTILISATIONS
  申请人：NIMBUS CLIO INC

  公开号：WO2022217276A1

  公开（公告）日：2022-10-13

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibtion of Cbl-b, and the treatment of Cbl-b-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们的方法，用于抑制Cbl-b和治疗Cbl-b介导的疾病。
• Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)
  作者：Gregory S. Basarab、Pamela J. Hill、C. Edwin Garner、Ken Hull、Oluyinka Green、Brian A. Sherer、P. Brian Dangel、John I. Manchester、Shanta Bist、Sheila Hauck、Fei Zhou、Maria Uria-Nickelsen、Ruth Illingworth、Richard Alm、Mike Rooney、Ann E. Eakin

  DOI：10.1021/jm500462x

  日期：2014.7.24

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.